Tenderwize
Wróć do wyszukiwania

Non-exclusive Drug Rebate Agreement for Tolvaptan

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2026 · 4 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tolvaptan (ATC-Code: G04BX21)

30/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

30 / 100

Złożoność

25 / 100

Czynniki ryzyka

No minimum purchase quantities. Actual demand depends on prescription behavior and patient count. Revenue cannot be pre...

Buyer may terminate the entire open-house procedure if exclusive agreements are signed, likely within 8-12 months from...

Submission deadline in 4 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2026
  • Conclusion of non-exclusive rebate agreements under § 130a Abs. 8 SGB V for pharmaceuticals containing Tolvaptan (ATC G04BX21)
  • Open-house model – no exclusivity, no individual negotiations
Pokaż pełne podsumowanie

This non-exclusive drug rebate agreement (Open-House model) for Tolvaptan (ATC G04BX21) allows all interested pharmaceutical companies meeting the requirements to conclude a rebate agreement with AOK PLUS. There is no exclusivity, no guaranteed purchase volumes, and individual negotiations are not conducted. The agreement runs until 31 August 2026, with early termination possible if exclusive agreements are concluded. Participation is via the DTVP portal, with initial applications due by 6 August 2024, and subsequent deadlines as per the schedule. Note that the notice is published for transparency purposes and is not a public procurement under EU directives.

Ryzyka

No minimum purchase quantities. Actual demand depends on prescription behavior and patient count. Revenue cannot be pre...

Buyer may terminate the entire open-house procedure if exclusive agreements are signed, likely within 8-12 months from...

Submission deadline in 4 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products
  • Place of business must be in Germany, EU, or EEA (per § 9 Abs. 2 AMG)

Eligibility

  • Submit declaration of no conflict of interest and no exclusion grounds under §§ 123, 124 GWB

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive Drug Rebate Agreement for Tolvaptan

Open-house model for non-exclusive rebate agreements on pharmaceuticals containing the active substance Tolvaptan (ATC code G04BX21). All qualified pharmaceutical entrepreneurs can join. No minimum volumes, unknown demand, agreement ends by 31 August 2026.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Aug 2024 - Aug 2026

Kategoria

Pharmaceutical products

Termin

Deadline Aug 31, 2026

Szczegóły zamówienia

Data publikacji
04 Jul 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
397500-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3